Core Viewpoint - The company is facing internal dissent regarding its proposed acquisition of 100% equity in Chengli Bio, with independent director Tao Hua'an expressing concerns about the necessity of the merger at this stage [1][2][3]. Group 1: Acquisition Proposal - The company plans to acquire 100% equity of Chengli Bio for a total transaction price of 1.4505 billion yuan, with 710 million yuan to be paid in cash [3]. - The acquisition aims to enhance the company's client resources in preclinical research and expand its customer base for cell culture products and CDMO services [4]. - Tao Hua'an has consistently voted against or abstained from the acquisition proposals, arguing that the company does not currently require such a merger [2][5]. Group 2: Financial Performance - The company's net profit for 2024 was reported at 21.0523 million yuan, a decrease of 61.04% year-on-year, while the net profit after deducting non-recurring gains and losses was 6.5859 million yuan, down 81.03% year-on-year [4]. - The company has faced significant losses in its CDMO business, with a 40.80% year-on-year decrease in operating profit [4]. - The company reported a substantial impairment loss of 9.5369 million yuan for its CDMO asset group, marking a 2176% increase year-on-year [6]. Group 3: Market Conditions - The CRO business of Chengli Bio is facing intense competition domestically, and there are uncertainties in its overseas operations [5]. - The global CDMO industry has entered a downturn since 2023, leading to a reassessment of the company's investment strategies and a reduction in planned capacity [6].